Joseph P. McEvoy - Concepedia

Author

Joseph P. McEvoy

Also Known As

Charles, Cecil, Davis, Sonia M., Harms, Michael P., Hays, Spencer, J McEvoy, J P McEvoy, J. P. McEvoy, J.P. McEvoy, JOSEPH McEVOY, JOSEPH P. MCEVOY

333

Publications

29.1K

Citations

H-Index

162

Concepts

All Affiliations

Duke University Duke Medical Center University of North Carolina at Chapel Hill Columbia University Duke University Hospital

About

Joseph P. McEvoy is an author at Duke University specializing in medicine, psychiatry, and schizophrenia.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	57	97	12.2K
2	Public Health	6	6	1.3K
3	Health Sciences	5	5	101
4	Nursing	2	2	132
5	Education	1	1	12

Joseph P. McEvoy

161

Publications

27.3K

Citations

H-Index

Page 1

	Year	Citations
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia Jeffrey A. Lieberman, T. Scott Stroup, Joseph P. McEvoy, New England Journal of Medicine	2005	5.9K
Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Joseph P. McEvoy, Jonathan M. Meyer, Donald Goff, Schizophrenia Research Intervention EffectivenessMetabolic SyndromeMetabolic DisorderPsychiatryPsychotic Disorder	2005	1.1K
A National Study of Violent Behavior in Persons With Schizophrenia Jeffrey W. Swanson, Marvin S. Swartz, Richard A. Van Dorn, Archives of General Psychiatry	2006	788
Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment Joseph P. McEvoy, Jeffrey A. Lieberman, T. Scott Stroup, American Journal of Psychiatry PsychiatryPsychotic DisorderPsychotropic MedicationRebound EffectClinical Trials	2006	748
The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development T. Scott Stroup, Joseph P. McEvoy, M S Swartz, Schizophrenia Bulletin	2003	642
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline Henry A. Nasrallah, Jonathan M. Meyer, Donald Goff, Schizophrenia Research HypertensionPsychiatryAntihypertensive TherapyDiabetesSchizophrenia	2006	553
Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective Disorder Robert M. Bilder, Robert Goldman, Jan Volavka, American Journal of Psychiatry	2002	537
Insight in Schizophrenia. Its Relationship to Acute Psychopathology Joseph P. McEvoy, L. Joy Apperson, Paul S. Appelbaum, The Journal of Nervous and Mental Disease NeuropsychologyPsychiatryStructured ScalesPsychotic DisorderPsychology	1989	530
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls Donald Goff, Lisa Sullivan, Joseph P. McEvoy, Schizophrenia Research Risk PredictionPsychiatryCardiovascular DiseasePsychotic DisorderCatie Study	2005	526
Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial Richard S.E. Keefe, Robert M. Bilder, Philip D. Harvey, Neuropsychopharmacology Catie Schizophrenia TrialNeuropsychological FunctioningNeuropsychologyPsychiatryPsychotic Disorder	2006	467

Page 1